Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations.
Yanhua WangJingwen WeiManyi XuJing XiangKeda ShaoYue HaoZhengbo SongPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
NSCLC patients with MET alterations can benefit from immunotherapy, especially the patients treated by combined ICI therapy. However, special attention should be paid to the occurrence of grade 3/4 adverse reactions while using the combined ICI therapy.